A Phase 3 clinical trial, NCT04596631, was listed as completed as of August 21, 2026. The study, titled "A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes," evaluated oral semaglutide against a placebo. The trial enrolled children and teenagers with type 2 diabetes and was registered on ClinicalTrials.gov. This update pertains to the trial's status designation only. The registry entry confirms the phase as Phase 3 and the status as completed, without reporting outcome data. No efficacy or safety results are included in this update. Readers should note this brief reflects only the status change recorded in the trial registry as of the stated date. Further details about study design, endpoints, or eventual findings would be published separately if and when results are posted to the registry or in a peer reviewed journal. For general background on calcitonin, readers can consult the compound overview page for additional context.
Oral Semaglutide Pediatric Phase 3 Trial Marked Completed
See the full calcitonin overview
Source: https://clinicaltrials.gov/study/NCT04596631